The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Approval of Myqorzo was granted to Cytokinetics.
Continue Reading
News Source: medicalxpress.com
Leave a Reply